Marzano AV, et al. - Authors correlated baseline levels of two proposed biomarkers, total IgE (bIgE) and D-dimer (bD-dimer), and clinical parameters to omalizumab response and to relapses after drug withdrawal. In chronic spontaneous urticaria (CSU), bIgE was confirmed as a reliable biomarker predicting response to omalizumab, while the usefulness of bD-dimer was not supported in the findings, unlike previous findings. Results demonstrated the probability of CSU duration before omalizumab and baseline UAS7 to be clinical markers of relapse risk.